Pacific Bio (PACB) Tops Q2 EPS by 6c, beats revenue

Pacific Bio (NASDAQ: PACB) reported Q2 EPS of ($0.26), $0.06 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $47.57 million versus the consensus estimate of $40.2 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• BIG3 Basketball to go public via Graf Global merger at $290 million
• UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results